
Jennifer Kolb Michener
Supervisory Patent Examiner (ID: 19087, Phone: (571)272-1424 , Office: P/1758 )
| Most Active Art Unit | 1762 |
| Art Unit(s) | 1776, 1758, 1762, 1728, 1600, 1721 |
| Total Applications | 477 |
| Issued Applications | 245 |
| Pending Applications | 85 |
| Abandoned Applications | 161 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18725914
[patent_doc_number] => 20230340155
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Antibodies that Specifically Bind PD-1 and Methods of Use
[patent_app_type] => utility
[patent_app_number] => 18/331280
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331280
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/331280 | Antibodies that Specifically Bind PD-1 and Methods of Use | Jun 7, 2023 | Abandoned |
Array
(
[id] => 18817544
[patent_doc_number] => 20230391884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
[patent_app_type] => utility
[patent_app_number] => 18/329443
[patent_app_country] => US
[patent_app_date] => 2023-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18329443
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/329443 | Treatment of IgE-mediated diseases with antibodies that specifically bind CD38 | Jun 4, 2023 | Issued |
Array
(
[id] => 18725875
[patent_doc_number] => 20230340105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => NOVEL ANTIGEN BINDING MOLECULE FORMATS
[patent_app_type] => utility
[patent_app_number] => 18/318871
[patent_app_country] => US
[patent_app_date] => 2023-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47652
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318871
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/318871 | Antigen binding molecule formats | May 16, 2023 | Issued |
Array
(
[id] => 18726152
[patent_doc_number] => 20230340408
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => SONOGENETIC MODULATION OF CELLS EXPRESSING BACTERIALLY-DERIVED MECHANOSENSITIVE PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/311075
[patent_app_country] => US
[patent_app_date] => 2023-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22227
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311075
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/311075 | SONOGENETIC MODULATION OF CELLS EXPRESSING BACTERIALLY-DERIVED MECHANOSENSITIVE PROTEINS | May 1, 2023 | Pending |
Array
(
[id] => 18877567
[patent_doc_number] => 20240000936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS
[patent_app_type] => utility
[patent_app_number] => 18/310649
[patent_app_country] => US
[patent_app_date] => 2023-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13050
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18310649
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/310649 | KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS | May 1, 2023 | Pending |
Array
(
[id] => 19002056
[patent_doc_number] => 20240066127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => IL-12 POLYPEPTIDES, IL-15 POLYPEPTIDES, IL-18 POLYPEPTIDES, CD8 POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/308427
[patent_app_country] => US
[patent_app_date] => 2023-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 83133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 410
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18308427
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/308427 | IL-12 POLYPEPTIDES, IL-15 POLYPEPTIDES, IL-18 POLYPEPTIDES, CD8 POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USING THEREOF | Apr 26, 2023 | Pending |
Array
(
[id] => 18725874
[patent_doc_number] => 20230340104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 18/308338
[patent_app_country] => US
[patent_app_date] => 2023-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 135551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18308338
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/308338 | IL-21 polypeptides and targeted constructs | Apr 26, 2023 | Issued |
Array
(
[id] => 19701539
[patent_doc_number] => 12195548
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => Chimeric canine anti-CD20 antibody
[patent_app_type] => utility
[patent_app_number] => 18/303769
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 4289
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303769
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/303769 | Chimeric canine anti-CD20 antibody | Apr 19, 2023 | Issued |
Array
(
[id] => 19003682
[patent_doc_number] => 20240067753
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
[patent_app_type] => utility
[patent_app_number] => 18/192861
[patent_app_country] => US
[patent_app_date] => 2023-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12929
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18192861
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/192861 | Complex-specific antibodies and antibody fragments and its use | Mar 29, 2023 | Issued |
Array
(
[id] => 19018970
[patent_doc_number] => 20240075141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
[patent_app_type] => utility
[patent_app_number] => 18/186133
[patent_app_country] => US
[patent_app_date] => 2023-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18186133
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/186133 | CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS | Mar 16, 2023 | Pending |
Array
(
[id] => 18511409
[patent_doc_number] => 20230227558
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/183588
[patent_app_country] => US
[patent_app_date] => 2023-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183588
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/183588 | SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT | Mar 13, 2023 | Pending |
Array
(
[id] => 18646940
[patent_doc_number] => 20230292707
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => SYSTEMS AND METHODS FOR ADMINISTERING DERMAL AND TRANSDERMAL IMMUNOTHERAPY TOPICAL APPLICATION COMPOUNDS TO ANIMALS
[patent_app_type] => utility
[patent_app_number] => 18/117559
[patent_app_country] => US
[patent_app_date] => 2023-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18117559
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/117559 | SYSTEMS AND METHODS FOR ADMINISTERING DERMAL AND TRANSDERMAL IMMUNOTHERAPY TOPICAL APPLICATION COMPOUNDS TO ANIMALS | Mar 5, 2023 | Pending |
Array
(
[id] => 18860329
[patent_doc_number] => 20230414763
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => TRANSMUCOSAL AMPHIPHILE-PROTEIN CONJUGATE VACCINE
[patent_app_type] => utility
[patent_app_number] => 18/117752
[patent_app_country] => US
[patent_app_date] => 2023-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18117752
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/117752 | TRANSMUCOSAL AMPHIPHILE-PROTEIN CONJUGATE VACCINE | Mar 5, 2023 | Pending |
Array
(
[id] => 18522961
[patent_doc_number] => 20230233612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/176678
[patent_app_country] => US
[patent_app_date] => 2023-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38082
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176678
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/176678 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | Feb 28, 2023 | Abandoned |
Array
(
[id] => 18596088
[patent_doc_number] => 20230270879
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => Anti-B7-H4 Antibodies And Methods
[patent_app_type] => utility
[patent_app_number] => 18/176084
[patent_app_country] => US
[patent_app_date] => 2023-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176084
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/176084 | Anti-B7-H4 Antibodies And Methods | Feb 27, 2023 | Pending |
Array
(
[id] => 18449369
[patent_doc_number] => 20230190645
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => COMPOSITION AND METHOD FOR REDUCING ALLERGIC RESPONSE
[patent_app_type] => utility
[patent_app_number] => 18/170124
[patent_app_country] => US
[patent_app_date] => 2023-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 534
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18170124
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/170124 | COMPOSITION AND METHOD FOR REDUCING ALLERGIC RESPONSE | Feb 15, 2023 | Pending |
Array
(
[id] => 18537555
[patent_doc_number] => 20230242653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/164442
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164442
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164442 | Agonistic anti-IL-2R antibodies and methods of use | Feb 2, 2023 | Issued |
Array
(
[id] => 18739629
[patent_doc_number] => 20230348589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
[patent_app_type] => utility
[patent_app_number] => 18/160745
[patent_app_country] => US
[patent_app_date] => 2023-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160745
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/160745 | Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor | Jan 26, 2023 | Abandoned |
Array
(
[id] => 18497410
[patent_doc_number] => 20230220040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/101601
[patent_app_country] => US
[patent_app_date] => 2023-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28575
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18101601
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/101601 | PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF | Jan 25, 2023 | Abandoned |
Array
(
[id] => 18649440
[patent_doc_number] => 20230295251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => ALLERGY ANTIGEN AND EPITOPE FOR SAME
[patent_app_type] => utility
[patent_app_number] => 18/147789
[patent_app_country] => US
[patent_app_date] => 2022-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40736
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18147789
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/147789 | ALLERGY ANTIGEN AND EPITOPE FOR SAME | Dec 28, 2022 | Pending |